Replies to post #3553 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>Did Japan allow Anti-thrombin as an approved use for DIC based on any controlled studies they performed or based on anecdotal evidence.<

That’s a good question, but I do not know the answer. I will try to find out.

[DewDiligence]

This may be the answer to your question
about the basis for AT use in Japan for DIC:

http://sciencelinks.jp/j-east/article/200207/000020020702A0063586.php

>>
New Aspects in Management of Disseminated Intravascular Coagulation: DIC and Antithrombin

Uchiba, Mitsuhiro

Kumamotodai I Rinshokensaigaku

Japanese Journal of Intensive Care Medicine, 25:11 843-848 (2001).

Antithrombin is an important inhibitor of coagulation system. Antithrombin inhibits thrombin by interacting with heparin-like substrate on endothelial cells. In addition to regulate coagulation abnormalities, antithrombin regulates inflammatory reaction by increasing prostacyclin production from endothelial cells. Interaction of antithrombin with heparin-like substrate on endothelial cells is important for this effect. Antithrombin regulate endothelial cell activation directly. Exogenous administration of antithrombin is useful for treating patient with sepsis or other inflammation in addition to treat the patients with DIC.
<<